4 lutego 2022: W Indiach rak może mieć poważne skutki społeczne i ekonomiczne, zazwyczaj skutkując nędzą rodzinną i niesprawiedliwością społeczną. W tym demograficznie młodym kraju zgłaszane współczynniki zachorowalności na raka skorygowane o wiek są nadal dość niskie. W populacji liczącej 1.3 miliarda ludzi każdego roku wykrywa się nieco ponad 1 milion nowych przypadków raka. W kategoriach skorygowanych o wiek odzwierciedla to około jednej czwartej zachorowalności mężczyzn i kobiet obserwowanej w Europie Zachodniej. Z drugiej strony rak był odpowiedzialny za około 600000 700000–2012 XNUMX zgonów w Indiach w XNUMX r.
Według analizy Global Burden of Disease Study 2019 przeprowadzonej przez IHME, obraz nie różni się szczególnie na całym świecie. W 2019 roku liczba nowych przypadków raka przekroczyła 23 miliony, w porównaniu z 18.7 milionami w 2010 roku. W 2019 roku odnotowano 10 milionów zgonów z powodu raka, w porównaniu z 8.29 miliona w 2010 roku. Wyniki te wskazują odpowiednio na wzrost o 20.9 procent i 26.3 procent .
In both developing and developed countries, cancer is a leading cause of morbidity and mortality. The majority of the population in many low- and middle-income nations, including India, does not have access to a well-organized and well-regulated cancer care system. When a person is diagnosed with cancer, they are often forced to spend a lot of money on their own health. Such expenses can push entire families into poverty and, when paired with a lack of what are considered acceptable services, can jeopardize social stability. It can be easily said that cancer treatment in India is still in a nascent stage and huge development is required in this field.
There are two major problems cancer patients and their family members face when someone is diagnosed with cancer. One is, where will they get the best and most appropriate treatment, and two, how much money will be required for treatment? Second is the most important question, as the general population in India is still devoid of health insurance. We at CancerFax addresses both these problems. We help cancer patients find most appropriate and economical cancer treatment in India and abroad. CancerFax is working with more than 100 top cancer hospitals in 10 countries like Dana-Farber, Mayo Clinic, Boston Children’s Hospital, Sheba, Asan, Apollo, BLK, Artemis to name a few.
CAR T-Cell therapy is a breakthrough treatment for some kinds of lymphoma, leukemia and multiple myeloma. CancerFax helps patients enroll for Terapia CAR T-Cell treatment in the USA, Israel and China. Many patients who had previously relapsed blood tumors had no evidence of cancer after CAR T-Cell therapy. It has also aided in the rehabilitation of patients who have previously failed to respond to most traditional cancer therapies. There are more than 300 ongoing clinical trials in the world’s leading cancer centers on this therapy. CAR T-Cell therapy in India is available as clinical trials now. I hope it will be available for commercial treatment very soon.
